

Uric Acid Crystalluria following the Recovery Phase of Diabetic Ketoacidosis (DKA): A Lesser-known Complication of DKA

Yotsapon Thewjitcharoen, Nopparath Tongpoo, Worawit Kittipoom

Diabetes and Thyroid Center, Theptarin Hospital, Thailand

Key words: *crystalluria, uric acid, diabetic ketoacidosis*

The occurrence of hyperuricemia is frequently associated with diabetic ketoacidosis (DKA),¹ however, crystalluria from the precipitation of calcium oxalate, uric acid, or urate crystals, is less known. Metabolic derangements during

DKA, especially acidic urinary pH and hyperuricosuria are the main risk factors for uric acid crystals and stones.² Here we report a case of uric acid crystalluria following the recovery phase of DKA.




Figure 1. Urine sediment displays different types of shapes: barrel, plate-like, or diamond, consistent with uric acid crystals (x10); Diamond and rhomboid-shaped uric acid crystals at a higher magnification (x40).

A 72-year-old male with persistent poorly controlled Type 2 DM was admitted due to COVID-19 pneumonia and severe DKA. On admission, his baseline serum creatinine increased from 1.3 mg/dL to 2.1 mg/dL. After intravenous insulin infusion and hydration, DKA was resolved after 15 hours with improved renal function to baseline. After DKA resolution, urinalysis showed an incidental finding of uric acid crystal particles with an acidic urine pH of 5.0. The concurrent level of plasma uric acid was within normal (6.6 mg/dL). Plain abdominal CT revealed no stones in the renal medulla or ureters. However, earlier blood samples on admission showed markedly elevated plasma uric acid levels (12.1 mg/dL). Further investigations revealed increased fractional excretion of uric acid from 7.4% at admission to 15.7% on the second day, indicating hyperuricosuria. With adequate diuresis and supportive treatment, crystalluria disappeared within 48 hours and he was discharged after 10 days. Our case highlights the importance of urine microscopy examination in patients with severe DKA to detect crystalluria which might contribute to renal impairment or nephrolithiasis following the recovery phase of DKA if left unchecked.³ Clinicians should consider hyperuricemia which could lead to uric acid nephropathy from kidney stone as a late complication of DKA.

Ethical Consideration

Patient consent was obtained before submission of the manuscript.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

CReditAuthor Statement

YT: Conceptualization, Methodology, Validation, Data curation, Writing – original draft preparation, Visualization, Funding acquisition; **NT:** Investigation, Project administration; **WK:** Software, Resources, Writing – review and editing, Supervision.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. Padova J, Bendersky G. Hyperuricemia in diabetic ketoacidosis. *N Engl J Med.* 1962;267: 530-4. PMID: 14483098. <https://doi.org/10.1056/NEJM196209132671102>.
2. Agrawal N, Kremser R, Uysal S, Fredette ME, Topor LS. Nephrolithiasis: A complication of pediatric diabetic ketoacidosis. *Pediatr Diabetes.* 2018;19(2):329-32. PMID: 28737266. <https://doi.org/10.1111/pedi.12559>.
3. Shimazaki S, Kazukawa I, Mori K, Kihara M, Minagawa M. Acute kidney injury caused by ammonium acid urate crystals in diabetic ketoacidosis at the onset of type 1 diabetes mellitus. *Endocrinol Diabetes Metab Case Rep.* 2021;2021:20-0143. PMID: 33865236. PMCID: PMC7923033. <https://doi.org/10.1530/EDM-20-0143>.

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (*optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.



Clinical controversies and disease updates are also welcome. Instructions to Authors available at www.ASEAN-endocrinejournal.org.